Zevra To Present Long-Term MIPLYFFA Data In Niemann-Pick Disease At SSIEM 2026

Summary

Zevra Therapeutics will showcase long-term data on its drug MIPLYFFA for Niemann-Pick disease type C at the 2026 SSIEM Annual Symposium. The findings indicate sustained disease stabilization in patients across various demographics, with treatment durations of up to eight years and a favorable safety profile. The drug, which received FDA approval in September 2024, showed a significant reduction in disease progression in prior trials. Currently, Zevra's stock is experiencing slight fluctuations in pre-market trading.

Key takeaways

• Zevra will present long-term data on MIPLYFFA at SSIEM 2026.
• The drug has shown sustained disease stabilization and a good safety profile.
• Zevra's stock has fluctuated between $7.16 and $15.03 in the past year.